Hightide Therapeutics IncHKEX: 2511

2026 Interim Report

Sep 29, 2026 at 10:01 PM UTC · HKEXnews

HKEX: 2511

View Attachment

Original release on HKEXnews

Earlier from Hightide Therapeutics

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate...Jun 7, 2024

All Hightide Therapeutics news releases